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Abstract
The infectious disease from Coronavirus Disease 2019, or COVID-19, has quickly spread world-wide since 2019. Therapies for managing COVID-19 have
yet to be confirmed as medication for the severe sickness that the disease may cause. This study aimed to review the previous research of the efficacy of trial
therapy and treatment to the patients in the hospital with COVID-19. Using PRISMA guidelines as a method for conducting a systematic literature review, a
total of 67 articles were collected from several online journal databases. Various therapies were found that are effective in the treatment and management of
COVID-19. In accordance with the inclusion and exclusion criteria of this study, a total of 8 articles were selected. The study showed that several therapies
are effective in managing the severe illness, can be used as COVID-19 treatment. Combination of medicine have shown the effectiveness of clinical improve-
ments and recovery rate in a short time compared to single medicine. Nevertheless, further study into effective therapies for COVID-19 must be continued to
find the best therapy and treatment.  
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Introduction
The emergence of the infectious disease known as
Coronavirus Disease 2019 (COVID-19) began in Wuhan
at the end of 2019.1 The causative agent of COVID-19 is
the same as the virus from severe acute respiratory syn-
drome (SARS) disease. The first infection of SARS was
found in the South China last month in 2002.2
The virus has spread rapidly worldwide, and was re-
ported by the World Health Organization (WHO) in
January 30, 2020.3 Thus far, as of June 2020 the corona -
virus has affected 215 countries and territories, with over
6,190 confirmed cases, and over 376,300 deaths.4 In
Indonesia, cases confirmed by the Ministry of Health are
over 28,200 and confirmed deaths over 1,600 cases.5
COVID-19 is a respiratory disease which can cause
fatigue, fever, dry muscle aches, coughs, shortness of
breath and in some instances lead to pneumonia.6,7 The
most common means of transmission occurs person to
person, including amongst family members, and also
from healthcare workers.8,9 There is no agreed medica-
tion to help recovery from COVID-19; the management
of medication is based on each patient’s sign and symp-
toms. The WHO advises to apply empiric antimicrobial
thera py and to implement mechanical ventilation based
on the clinical diagnosis of patients.10-12 The purpose of
this study was to review the previous research of the ef-
ficacy of trial therapy and treatment to the patients with
COVID-19. The study emphasizes that effective therapy
for COVID-19 to the patients should be able to accele -
rate the recovery of patients and the symptoms of
COVID-19 suffered by patients are not getting worse in
Indonesia.
Method
The research used Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines for conducting a systematic literature review.13,14
Authors chose relevant study published from January
2020 to March 2020, by searching Pubmed, Science
Direct and Google Scholar, with a total of 67 articles
found. 
The search terms used were "Coronavirus Disease
2019", "Novel Corona Virus 2019", "The Therapy for
Coronavirus Disease", "The Treatments for Severe Acute
of COVID-19”. Only articles written in English were con-
sidered. The study was focused on the treatment of
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SARS, virus MERS-Cov and SARS-CoV. Inclusion crite-
ria for this study are only articles on therapy and treat-
ment of COVID-19 given to patients in hospitals or
health servi ces. While the exclusion criteria of this study
are articles on COVID-19 prevention treatments in the
community. The screening was conducted by reading the
title, abstract, and full text of the articles.
Eligible studies on therapies and treatment for mana -
ging COVID-19 to the patients were perfomed in a sys-
tematic review table. This table showed the author and
year; country of publication of the trial therapy or treat-
ment; population/data source; efficacy measure; adverse
events; and lessons learned. Interpretation of the data is
done by using qualitative and quantitative approach. The
qualitative approach involved interpreting tables and
learning the lessons, while the quantitative approach in-
cluded assessing the efficiency rate of the therapy and
treatment reviewed.
Results
A total of 67 articles were obtained from three sources
(Figure 1); 16 articles from Google Scholar, 24 articles
from Pubmed, and 27 articles from Science Direct. Three
articles from these sources were copied articles. After
screening by reading 64 abstracts, 28 articles were ex-
cluded since they discussed preventive thera py in the
community, such as physical distancing, use of face
masks, or the symptoms of COVID-19. After screening
by reading the whole 36 articles, 28 articles were exclud-
ed since they only discussed the contain of medicines re -
commended for therapeutic use or treatment for COVID-
19. Therefore, the included articles according to the in-
clusion and exclusion criteria of this study were eight
quantitative studies.
Table 1 shows the systematic literature review of the
efficacy of therapy for managing COVID-19, while Table
2 shows the review of the efficacy of treatment for ma -
naging COVID-19. A total of eight studies were selected
for the review, showing that various therapies and inter-
ventions were effective in handling COVID-19. 
Based on Table 1, a combination of medicines was
better than one type of medicine. The level of clinical pa-
tient improvement on day 14 was higher in the Lopinavir
(LPV) - Ritonavir (RTV) group than in the standard care
group (45.5% vs 30.0%). In the study of Arbidol com-
bined with LPV/r (Lopinavir/Ritonavir), after 14 days in
15 (94%) out of 16 patients, COVID-19 could not be de-
tected at p-value of less than 0.05. After six days of treat-
ment, all the six patients (100%) at the group of
Hydroxychloroquine combined with Azithromycin were
tested negative of COVID-19. 
Table 1 also shows the evaluation of the adverse
events of the reviewed studies. Study Cai, et al.,17
Favipiravir (FPV) patients had two cases of diarrhea, one
liver injury case, and one poor diet case), while study
Chen, et al.,20 found that FPV increased serum uric acid
(16 /116), with OR = 5.52 at p-value of less than 0.005).
LPV/RTV patients had five cases of diarrhea, five vo -
miting cases, six nausea cases, four rash cases, three liver
injury cases, and two cases of chest tightness and palpi-
tation. Two patients in the group of Arbidol was diag-
nosed with leukopenia (white blood cell count < 4 x
109/L). In one study which combined Arbidol with
LPV/r, 68.7% of patients demonstrated elevated levels
of bilirubin, with a top mean of 25.26 μmol/L (10.61
μmol/L).
Not only the use of drugs, but also treatment by pro-
gressive muscle relaxation and sunbathing can also in-
crease healing (Table 2). Progressive muscle relaxation is
useful in reducing stress for COVID-19 patients, espe-
cially in hospitals.
Discussion
Based on the results of this study, it appears that there
are drugs that can be used to cure patients of COVID-19;
for example, antiviral and antimalarial medicines, such
as Lopinavir/ Ritonavir, Fapiviravir, Arbidol, and
Hydroxy chloroquine. The study results of Zhu, et al.,16
show that the side effects that need to be considered in-
Figure 1. PRISMA Diagram Flow of the Efficacy of Therapy and Treatment
for Managing COVID-19
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clude two patients who had leucopenia when using
Arbidol. Another effect found in the study by Cai, et
al.,17 was that using FPV that can cause diarrhea and li -
ver injury. The advice to medical personnel in Indonesia
is that they should also pay attention to these side effects
if some of these therapies will be prescribed to patients
Table 1. Systematic Literature Review the Efficacy Therapy for Managing COVID-19
Author                Year    Country    Population / Data Source         Therapy                       Efficacy Measure           Adverse Event                   Lesson Learn
Cao et al.,15        2020   China        When adult patients have un-    Lopinavir (LPV) –       Clinical improvement     Lopinavir/Ritonavir:          Lopinavir-Ritonavir
                                                       der treatment of COVID-19.     Ritonavir (RTV)          at day 14:                       four serious gastro-            treatment more effective
                                                       RTV and LPV with standard     versus standard care    The LPV and RTV are   intestinal.                           beyond standard care
                                                       care group 99 patients. Only                                         45,5 % and standard     Standard care:                    only.
                                                       standard care 100 patients.                                            care only are 30%.         respiratory failure,
                                                                                                                                                                                   acute kidney injury,
                                                                                                                                                                                   and secondary infect-
                                                                                                                                                                                   ion common in the
Zhu, et al.,16       2020   China        After laboratory checked, 50     Arbidol monothera-     On day 14, viral             Diagnosed with leuko-       Arbidol monotherapy
                                                       patients confirmed with             py versus Lopinavir/    load Arbidol group        penia:                                 more effective than
                                                       COVID-19. They are divided     Ritonavir                      was detectable in           Lopinavir/Ritonavir           Lopinavir-Ritonavir
                                                       into two groups: including                                             all the patient.                group: 1 patient; Arbi-
                                                       lopinavir/ritonavir group                                               Lopinavir / Ritonavir     dol group: 2 patients
                                                       (34 cases) and Arbidol group                                        was found in 44.1%
                                                       (16 cases).                                                                  
Cai, et al.,17         2020   China        Patients of COVID-19 were       Favipiravir (FPV),        Viral clearance and        FPV patients had (2           FPV more effective
                                                       screened in The Third                versus Lopinavir          chest imaging rate:         diarrhea, 1 liver injury,      treatment for SARS-
                                                       People’s Hospital on                  (LPV)-Ritonavir           FPV (4 day, 91.43 %),  1 poor diet).                       Cov-2 patients during
                                                       Shenzhen. FPV (35 Patients),    (RTV)                          LPV/RTV (11 day,         LPV/RTV patients had       the growth and settle- 
                                                       LPV/RTV (45 patients)                                                 62.22%)                        (5 diarrhea, 5 vomiting,     ment of viral virus.
                                                                                                                                                                                   6 nausea, 4 rashes, 3 
                                                                                                                                                                                   liver injury, 2 chest
                                                                                                                                                                                   tightness and palpita-
                                                                                                                                                                                   tion).
Gautret, et al.,18 2020   France      The population located in          Hydroxychloroquine    After 6 day of inclu-       Potential risk has not         Hydroxychloroquine
                                                       Marseille at the University         only versus combined  sions, a number of         been established yet           treatment is significant-
                                                       Hospital.                                    with Azithromycin       negative patients:                                                      ly associated with the
                                                       Hydroxychloroquine group                                            Hydroxychloroquine                                                 reduction of the virus
                                                       (14 patients),                                                                 with Azithromycin                                                    disappearance and Azi-
                                                       Hydroxychloroquine with                                              (6/6 patients, 100%)                                               thromycin reinforced its
                                                       Azithromycin (6 patients),                                             Hydroxychloroquine                                                 effect.
                                                       control patients (16).                                                 only (3 /13 patients,
                                                                                                                                             57.1%), control pa-
                                                                                                                                             tients (2/16 patients,
                                                                                                                                             12.5%).
Deng, et al.,19     2020   China        Included adults (age ≥18          Arbidol combined        After 14 days, the          The proportion of pa-         The apparent favorable
                                                       years old) with laboratory-         with LPV/r versus       SARS-Cov-2 was not     tients who demonstrat-      clinical response with
                                                       confirmed COVID-19                LPV/r alone                 detected in therapy        ed elevated levels of bi-      Arbidol and LPV/r sup-
                                                       without invasive ventilation                                           using Arbidol combin-   lirubin were 68.7%,           ports further LPV/r 
                                                       and patient were given oral                                            ed with LPV/r in            with a top mean biliru-      only.
                                                       Arbidol and LPV/r in the                                               more than 94% pa-        bin was 25.26 μmol/L;
                                                       combination group and oral                                           tients. While Arbidol     43.7% of patients de-
                                                       LPV/r only in the monothe-                                           monotherapy only          monstrated digestive up-
                                                       rapy group.                                                                    worked in 52.9%           sets, such as mild diar-
                                                                                                                                             patients. Improving        rhea and nausea, but all
                                                                                                                                             the chest CT scans.        patients had no prema-
                                                                                                                                             11(69%) of 16 pa-         ture discontinuation se-
                                                                                                                                             tients in the combinat-   condary to adverse 
                                                                                                                                             ion group after seven     effects.
                                                                                                                                             days, compared with
                                                                                                                                             5 (29%) of 17 in the
                                                                                                                                             Monotherapy group.
Chen, et al.,20     2020   China        An entire data of 240 pa-           FVP against Arbidol    After 7 days of the cli-   The highest frequently        Favipiravir equaled to
                                                       tients with COVID-19 pneu-                                         nical recovery rate of     observed Favipiravir -        Arbidol, did not impor-
                                                       monia were hired from the                                            Favipiravir group 71      coalition adverse event      tantly to improve the
                                                       three hospitals (120 from                                              from 116 patients, the   was elevated serum uric     medical recovery rate
                                                       Zhongnan Hospital of Wuhan                                       Arbidol group only 62   acid (16/116).                    on day 7.
                                                       University (ZNWU), 88 from                                        from 120.                                                                 Favipiravir importantly
                                                       Leishenshan Hospital (LSS),                                         Favipiravir controlled                                               recover the latency to
                                                       and 32 from The Third People's                                    to petite latencies to                                                 respite for pyrexia and
                                                       Hospital of Hubei Province                                            relief for two of pyrexia                                            cough.
                                                       (HBTH)                                                                         and cough.
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of COVID-19.
The results of this study show that a combination of
drugs works better. In the research conducted by Deng,
et al.,19 it was shown that the combination of Arbidol
and Lopinavir/Ritonavir could accelerate healing for pa-
tients of COVID-19. On the 14th day of treatment, 94%
of patients receiving combination therapy showed nega-
tive signs of the SARS COV 2 virus. In research Gautret,
et al.,18 also combined Hydroxychloroquine with
Azithromycin in their study. On day 6 post-inclusion, the
number of negative patients was 6/6, 100%. The study
by Cao, et al.,15 which combi ned Lopinavir and Ritonavir
showed an improvement in the patient's health condition
at 45.5% on day 14. The effects that need attention are
serious gastrointestinal adverse events with Lopinavir
and Ritonavir, elevated levels of bilirubin, and digestive
upsets, such as mild diarrhea and nausea in combined
Arbidol with Lopinavir/Ritonavir therapy.
Apparently, progressive muscle relaxation can help
reduce stress for COVID-19 patients. Based on medical
diagnosis, some coronavirus disease patients have sleep
disturbance and anxiety after isolation therapy. Anxiety
due to psychological stress could become a trigger of de-
creased immunity and physiological disorders.23
Progressive muscle relaxation (PMR) training reduced
the effect of anxiety on the patients, which might happen
due to the ba lance between the hypothalamic nucleus and
anterior. By reducing the activity of the sympathetic ner -
vous system, stress and anxiety can be prevented, and
physical and mental relaxation can be increased.24
Sunlight can also be applied to increase healing in pa-
tients COVID-19 as triggers the production of vitamin
D, which strengthens the immune system.25
Recently, to help progress in the study of the effect -
iveness of several therapies, WHO developed the solida -
rity clinical trial project for COVID-19 treatments.26 The
project aims to obtain strong and valid clinical evidence
for four potential therapies that have been tried. In
March 2020, the government of Indonesia joined the tri-
al.
In Indonesia, there is some development of pharma-
ceutical drug research in herbal trials. Universitas
Indonesia and the IPB University (Institut Pertanian
Bogor) research teams are also developing this line of
study with regard to antibodies and antivirals accessed
from guava, moringa leaves, and orange peel. These com-
positions include hesperidin, rhamnetin, kaempferol,
quercetin, and myricetin from the mixture of guava (pink
fruit skin), orange peel, and moringa leaves.27 The study
discusses research against the protein, and gathering
herbs related to the work of the virus, obtained several
related groups to prevent the SARS-CoV-2 virus (corona -
virus).27
The limitation of this study is to limit studies that have
been reviewed because there are still many trial therapy
studies that are being conducted in several other coun-
tries. This study also did not involve an additional popu-
lation variation, such as pregnant mothers and children,
so the efficacy and occurrence of adverse events for preg-
nant women and children could not have been explored
more in this study.
Conclusion
Several studies have shown the effectiveness of seve -
ral trial therapies and treatment for COVID-19. These
used a single drug or a combination of drugs, mostly from
the antiviral class. Progressive muscle relaxation and sun-
bathing treatment can also improve the healing process.
Medical personnel is expected to implement the results
of this study to COVID-19 patients in Indonesia.
Nevertheless, research about the effective therapies for
COVID-19 must be continued to find the best therapy
and treatment. Future studies on the treatment of
COVID-19 could be related to varying ages and condi-
Table 2. Systematic Literature Review the Efficacy Treatment for Managing COVID-19
Author                Year    Country    Population / Data Source         Therapy                       Efficacy Measure           Adverse Event                   Lesson Learn
Liu, et al.,21        2020   China        51 patients from Hainan            Progressive muscle       The anxiety (STAI)        No adverse event was         Progressive muscle 
                                                       General Hospital, China            relaxation                     score after a 5-day in-    found in this study.            relaxation can reduce
                                                                                                                                             tervention was signifi-                                              anxiety and improve
                                                                                                                                             cant (p-value < 0.001).                                             sleep quality in patients
                                                                                                                                             The sleep quality score                                             with COVID-19.
                                                                                                                                             (SRSS) after the 5-day 
                                                                                                                                             treatment was meaning-
                                                                                                                                             ful (p-value < 0.001).
Asyary, et al.,22   2020   Indonesia  Only 8% of hospitals are           Exposed directly to      After daily sunlight ex-   No adverse event was         Direct exposure to sun-
                                                       available to care for                  sunlight                        posure for a minimum   found in this study.            light was connected sig
                                                       COVID-19 patients, being                                            of 3 hours, deaths due                                              nificantly to recovery
                                                       emergency hospitals in                                                  to COVID-19 decreased.                                          from COVID-19 among
                                                       Jakarta.                                                                                                                                                          patients in Jakarta,
                                                                                                                                                                                                                              Indonesia. 
Notes: STAI: The Spielberger State-Trait Anxiety Scale; SRSS: Sleep State Self-Rating Scale
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tions, such as pregnant women and children.   
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